Insulin and hyperandrogenism in women with polycystic ovary syndrome.
about
Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-InositolAMP-activated protein kinase is a key intermediary in GnRH-stimulated LHβ gene transcriptionOmega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome.Polycystic ovary syndrome induced by exposure to testosterone propionate and effects of sympathectomy on the persistence of the syndrome.Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation.Assessing and treating insulin resistance in women with polycystic ovarian syndromeThe association between polymorphism of INSR and polycystic ovary syndrome: a meta-analysisPolycystic diseases in visceral organs.Prevalence and clinical predictors of insulin resistance in reproductive-aged thai women with polycystic ovary syndrome.Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism.Trace glucose and lipid metabolism in high androgen and high-fat diet induced polycystic ovary syndrome rats.Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feedingAssociation Analysis between the Polymorphisms of HSD11B1 and H6PD and Risk of Polycystic Ovary Syndrome in Chinese Population.The Obesity-Fertility Protocol: a randomized controlled trial assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women.Does ovary need D-chiro-inositol?Predictors of insulin resistance and metabolic complications in polycystic ovarian syndrome in an eastern Indian population.Functional link between bone morphogenetic proteins and insulin-like peptide 3 signaling in modulating ovarian androgen productionTriglycerides to High-Density Lipoprotein Cholesterol Ratio Can Predict Impaired Glucose Tolerance in Young Women with Polycystic Ovary SyndromeSaturated fatty acid exposure induces androgen overproduction in bovine adrenal cells.Effects of diet-induced obesity on metabolic parameters and reproductive function in female Ossabaw minipigsBenefits of omega-3 Fatty acids supplementation on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome.Psychological aspects of the polycystic ovary syndrome.The effects of being overweight and obese on female reproduction: a review.Steroidogenesis-adrenal cell signal transduction.Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies.Preventive and Therapeutic Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of Evidences and Future Applications.Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs).PHYSIOLOGY AND ENDOCRINOLOGY SYMPOSIUM: Insulin action and lipotoxicity in the development of polycystic ovary syndrome: A review.The Presence of Human Chorionic Gonadotropin/Luteinizing Hormone Receptors in Pancreatic β-Cells.Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective, population-based cohort study.Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy.Authors' reply to: "Empiric" inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects."Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects.Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: A randomized double-blind placebo controlled clinical trial.Endocrine-disrupting chemicals in human follicular fluid impair in vitro oocyte developmental competence.Association of -604G/A and -501A/C Ghrelin and Obestatin Prepropeptide Gene Polymorphisms with Polycystic Ovary Syndrome.Therapeutic approach for metabolic disorders and infertility in women with PCOS.Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome.
P2860
Q28251963-530E6A0E-5973-4919-966A-D8CDB6D8D720Q30413428-1BEE9875-9AB8-4B66-BD8A-D4F6CB3E961CQ33771216-55024764-9835-44B7-8649-462DCBC27904Q33891765-FA48482E-D959-4C81-84CE-AE355FEC4B93Q34766224-4E552F9D-A7BB-470F-A63A-49CA44EC246EQ34878055-67E652C8-D9DD-4F82-A904-C89047867380Q35138875-DC0F68A3-5936-46D6-A450-2A240D153AA0Q35660081-03C568BE-504C-44EC-AFAF-10F52375FC4EQ35687495-B343D3DF-32CA-4C91-9A3A-99D92B5DAAECQ35747110-E4F99B25-3019-408B-9B51-9DA2D7FF11D6Q35753559-0F84F3E8-0836-4663-9ED5-FDFDE06CE053Q35790276-24DC7400-05F2-49CD-8273-090AE7BB35ACQ35801880-AF0CCF39-AD78-4E65-BC3F-78637C818256Q35860762-513E6707-F520-4C57-A951-16C151358284Q36249155-841201DE-E6DE-45F4-ABA0-571997FB1602Q36732197-64705FAB-ED86-4C57-A1B1-0BDF3E04BA00Q36762746-DF0AE6DA-22EB-472F-AA4D-BDAF98D8DA33Q37231872-4907AB00-6C52-42A0-AA7B-A364FA4DAD5CQ37360333-25FC8E9B-2640-461C-A557-61ED180A070BQ37593298-5FDE112C-319E-4CC2-AE1D-50DD7340158CQ37658882-0BCE1F79-5F5F-4F08-9259-5019E90BDE6BQ38159777-325074DF-D283-4E97-B0EE-3B7D2405847AQ38159778-1BAD2FC9-1A07-434F-B1B5-02771E246375Q38221447-AEA3AFF4-A27D-4661-993B-767FDEABEE47Q38254184-E1ECBBD0-956B-4D8C-8DE4-D9251180D1FFQ38547308-0F1B186C-40AF-4A96-8539-C9A5929A2349Q38716040-405E7074-F76C-4497-9D06-581C76794E06Q38861206-5F8A3F86-1E03-4FFC-9989-D26D5A9B0BAEQ38910863-982CD3E9-2BC3-41B4-97D5-E91FB9A2EAF5Q38949684-F62CF6D7-77D8-4F34-9E6A-B11A32E7F8EFQ40386727-4CAD4930-71EB-4E58-9F29-84FF39DF6515Q40404052-49D7ECE4-6C76-4D4D-928B-29C4E1E5F9D6Q41116375-EFC1061D-3B14-4866-BBCD-56DA4452E7B2Q47405236-96856264-E409-44AE-B509-2E8071463243Q47405250-26E2B16E-37AC-4279-8940-B7478A471497Q48102672-1185CB83-2CF5-424F-BF73-3D99BF9F4D50Q48656899-80CC0AB3-8759-45A2-9708-87DC13F8C720Q49914138-BA815BDE-B428-49FF-AD5C-0D5FE6A79EAAQ50428675-2321B0A0-576E-4BCF-B69A-052C0AB2B08AQ51257727-13B5CB9A-B08F-4199-85C8-ABE63DB017DB
P2860
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@en
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@nl
type
label
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@en
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@nl
prefLabel
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@en
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@nl
P2093
P2860
P1476
Insulin and hyperandrogenism in women with polycystic ovary syndrome.
@en
P2093
Andréanne Trottier
Catherine G Baptiste
Jean-Patrice Baillargeon
Marie-Claude Battista
P2860
P356
10.1016/J.JSBMB.2009.12.010
P577
2009-12-28T00:00:00Z